Conference Exhibitors

Abbott is a global leader in point-of-care (POC) diagnostics with a comprehensive portfolio of rapid tests, services, and handheld devices for use in a wide variety of healthcare settings: labs, clinics, remote healthcare outposts, retail outlets, the patient’s bedside and at home. Abbott’s offering of near-patient tests and services spans key health and therapeutic areas, including infectious disease, cardiometabolic, informatics, toxicology and consumer diagnostics.

Based in Parma, Italy, Chiesi Farmaceutici is an international research-focused biopharmaceuticals group with over 85 years’ experience in the pharmaceutical sector operating in 30 countries, employing around 6,000 people. Chiesi develops and markets innovative therapeutic solutions in respiratory health, rare diseases, and specialty care. The company’s mission is to improve people’s quality of life and act responsibly towards both the community and the environment. As a certified B Corp since 2019, Chiesi is part of a global community of businesses that meet high standards of social and environmental impact. Chiesi Limited is headquartered in Manchester employing over 400 people. www.chiesi.uk.com

Cipla (EU) Limited is a wholly-owned subsidiary of Cipla Limited, a global pharmaceutical company ranked No.2 (in FY’22) in the worldwide sale of respiratory inhalers by volume. (Cipla Annual Report 2022-23)

In 2013, Cipla commenced direct-to-market operations in the UK. Since then we have added a range of respiratory products, hospital products and have entered the oncology segment. Today, economies of scale and support from our global R&D and manufacturing teams has enabled us to deliver high quality products, and with product introductions, we aim to expand our range of branded and generic products in the UK.

Part of the Flexicare Group, Clement Clarke International (CCI) is a UK-based manufacturer, supporting clinicians worldwide to enhance patient outcomes with class leading innovative devices.

As a sustainability-focused UK manufacturer, Clement Clarke International (CCI) continues to be a major force in the manufacture of innovative respiratory devices, with stock levels consistently available for shipping anywhere in the world.

With over 100 years of history, CCI’s primary purpose and mission is to enable Health Care Professionals to Diagnose, Assess, Train and thereby Control their patient’s respiratory condition, keeping their respiratory patients well and at home.

CCI has the requisite portfolio of devices to support the patient journey from diagnosis through to effective self-management, helping prevent disease exacerbation and deterioration, thus improving their quality of life. This portfolio includes the unique CCI Inhaler Training Technique Toolkit, the essential armamentarium for asthma assessments.

Evidence and Health Care Professional (HCP) education and continuous improvement are of the highest importance to CCI. Their product range is supported by over 100 studies to date, and the Clement Clarke International Respiratory Training Academy offers HCP educational support delivered by UK respiratory experts.

Headquartered in the UK, our global network of 17 subsidiaries supports over 105 countries with dedicated in-market clinical experts and customer service centres.

Our regional teams are committed to providing swift solutions tailored to individual requirements.

Find out more at www.flexicare.com

Consilient Health, a well-established pharmaceutical company founded in 2005, is
dedicated to addressing unmet clinical needs while ensuring quality and savings for the NHS. With a strong focus on bone health, women’s health, and urology, we
extend our commitment to innovative solutions for ADHD and smoking cessation.
Visit www.consilienthealth.com for details.

UK-SH-79(1)a(2) January 2024

Glenmark Pharmaceuticals Europe Limited
Glenmark Pharmaceuticals is a global pharmaceutical company with a track record of improving patients’ lives through access to affordable medicines. As a leader in generics, we’re leveraging our industry expertise and success to fuel extensive research and delivering high-quality medicines that impact human lives.

GSK are a global biopharma company with a purpose to unite science, technology and talent to get ahead of disease together. We aim to positively impact the health of 2.5 billion people by the end of 2030. Our bold ambitions for patients are reflected in new commitments to growth and a step-change in performance.
NP-GB-RS-COCO-230002 | January 2024

Lupin Healthcare are proud to provide high quality medicines to patients that deliver both quality and value to the NHS.

Today’s portfolio consists of Respiratory and Neuromuscular medicines and high quality generics with a focus on anti-retroviral and oral contraceptives.

NSHI Ltd are a leading supplier of nursing services, cutting-edge technology solutions and comprehensive educational training, catering to the needs of both the NHS and Pharmaceutical sector clients. Positioned at the forefront of patient support, NSHI operates seamlessly across an extensive network of healthcare facilities, ensuring high quality care.

Our dedicated teams have positively impacted the lives of patients across more than 6,500 practices and 25 Hospital Trusts, driving our commitment to improve patient outcomes.

NSHI nursing services provide guideline level reviews for patients with asthma, COPD, cardiovascular disease, migraine, and other long-term conditions. Beyond patient care, we play a crucial role in supporting locality wide initiatives, delivering essential spirometry assessments, and actively participating in the national immunisation program.

Our services have evolved to incorporate training and education through the NSHI Academy, with our experienced team providing comprehensive respiratory training and education to clinical staff.

Working in Partnership with ICBs, TLHC and private sector clients we tailor our services to meet the needs of healthcare professionals across the UK. Through our specialised training initiatives in respiratory care, cardiovascular health and diabetes management, we aim to bridge gaps in knowledge and practice, empowering clinicians to provide optimal care and support to individuals dealing with respiratory health challenges.

NSHI is committed to advancements in healthcare technology, developing medical software solutions in collaboration with our sister organisations, LungHealth and SleepHealth Solutions. Our software is designed to support practices who may not have the benefit of specialist nurses or to augment existing specialist resources in Hospital Trusts.

Through seamless integration and user-friendly interfaces, our software provides healthcare professionals with the tools they need to navigate complex medical scenarios with confidence and efficiency, empowering them to deliver efficient and effective care to patients.

Highly skilled specialist nurses, together with cutting edge technology will see our healthcare solutions introduced to new markets worldwide. This strategic expansion supports our commitment to drive positive change and improve healthcare access and quality on an international scale.

NIOX® develops and produces state-of-the-art technology for asthma diagnosis and management. Our aim is to improve the lives of people suffering from asthma by helping physicians assess patients more accurately. Our market-leading device, NIOX VERO®, measures the level of fractional exhaled nitric oxide (FeNO) in the breath, with results proven to help with asthma treatment.(1-3)

NIOX® was the first to commercialise FeNO testing over 25 years ago. Today, we’re proud to say NIOX® remains the gold standard device(4), with more than 50 million tests performed worldwide and counting.

1. Carroll 2016. 2. Hanania 2018. 3. Price 2018. 4. Data on File; MKT-DOF-007. 2023.

Orion Pharma (UK) Ltd. is a subsidiary of Orion Corporation, pharmaceutical company based in Finland. We are continuously developing new drugs and treatment methods. The core therapy areas of our pharmaceutical R&D are oncology and pain. UK therapy areas include Respiratory, Women’s Health & Neurological disorders.
www.orionpharma.co.uk

July 2023/CORP-233(3)

Based in Redwood City, California, and Neuchâtel, Switzerland, Pulmonx is the maker of the Zephyr Valve. The Zephyr® Valve was granted breakthrough status and approved by the FDA in June 2018, because according to the FDA it “represents a breakthrough technology as the device offers bronchoscopic lung volume reduction without surgery and its associated risks. This device offers a significant, clinically meaningful advantage over the current standard of care and therefore, its availability is also in the best interest of patients.”
The company’s commercially available portfolio includes the Zephyr Valve. More than 100 scientific articles have been published on the clinical benefits of Zephyr Valves, including multiple meta-analyses, review articles, cost-effectiveness analyses and risk-benefit analyses.

We are an innovative global healthcare company, driven by one purpose: we chase the miracles of science to improve people’s lives. Our team, across some 100 countries, is dedicated to transforming the practice of medicine by working to turn the impossible into the possible. We provide potentially life-changing treatment options and potentially life-saving vaccine protection to millions of people globally, while putting sustainability and social responsibility at the center of our ambitions.

Interested in monitoring asthma patients before and after an asthma review? Or maybe after being discharged from ED? Or even to help diagnose their asthma when FeNO and spirometry aren’t conclusive? If so, visit the Smart Respiratory stand to learn more about the Asthma Virtual Ward. Patients receive an Asthma Virtual Monitoring Kit to self-monitor their asthma in the comfort of their homes and can share the data with their clinicians remotely or at a consultation. Clinicians can see the data via our Smart Asthma Dashboard and make data-driven clinical decisions using respiratory digital therapeutics (DTx).

Thornton & Ross, part of the STADA group, focuses on caring for people’s health through a broad portfolio including generics, biosimilars and non-prescription consumer healthcare products as a trusted partner supplying the NHS. STADA sells its products in more than 120 countries, employing over 12,000 people worldwide.

The Inhaler Tailor is a York-based start-up that makes fun & colourful cases for asthma & COPD medical inhalers (www.inhalertailor.com). They were designed with guidance from the MHRA as well as Asthma + Lung UK and go over the inhaler like a phone case. They're available in 36 different designs for all ages, covering a wide range of inhaler and spacer types.

The business featured on Dragons' Den as well as BBC Breakfast national news earlier this year. The NHS is also working on a study to quantify the impact of the cases on inhaler adherence among primary school children.

TidalSense’s mission is to bring about a paradigm shift in the practice of respiratory medicine, starting with bringing earlier, accurate and accessible COPD diagnosis to primary care.
This will be achieved by using N-Tidal, an easy-to-use device that relies on a patient’s normal relaxed breathing and incorporates a best in class CO2 sensor. This handset is combined with powerful artificial intelligence-derived algorithms that use the captured CO2 data to determine whether the patient has COPD or not. A diagnostic result is provided on the clinician dashboard within 5 minutes of starting the test, allowing it to be used at the point of care.
This test, called N-Tidal Diagnose, is anticipated to receive Class 2a EU MDR status in Q4 2024, with deployment already planned in at least one Integrated Care System in primary care. TidalSense is looking for NHS partners to help implement this improved pathway for patients with suspected COPD

Vitalograph products and services are chosen by medical professionals in over 113 countries for healthcare, occupational health, and clinical trials. We manufacture and supply high quality spirometers and respiratory medical devices which aid the detection, diagnosis and management of respiratory conditions.